Latest posts tagged with #Gu26 on Bluesky
A rationale for #SBRT to #Oligomets in #PSMA+BCR is “delay #ADT”
But this presupposes #PSMA+#BCR requires ADT/ARPI…
What if that’s not the case & most PSMA+BCR #ProstateCancer was indolent?
Thats what a study @theNCI shows @asco #Gu26
shorturl.at/IyBBT
WATCH 👀: @drchoueiri.bsky.social of @danafarber.bsky.social
discusses the potential clinical effects of data from the phase 3 LITESPARK-022 study. #kcsm #oncology #GU26 See the whole video here 📷: www.onclive.com/view/dr-chou...
COLLEAGUES AT #EAU26 Our friends from @GuardConsortium 🇪🇸Deliver another Great Informational Capsule, this time direct from #GU26 🇺🇸 We are proud to introduce our Colleague @mjuanfi81 Discussing the Presentation of:
KEYNOTE-B15/EV 304
PSA50 outcomes with lutetium Lu-177 vipivotide tetraxetan did not differ by race in patients with mCRPC, according to data from retrospective cohort study presented during @ascocancer.bsky.social #GU26 #oncology #pcsm #prostatecancer
Read more here: www.onclive.com/view/racial-...
WATCH 👀: @drchoueiri.bsky.social of @danafarber.bsky.social discusses safety data from the phase 3 LITESPARK-022 study in ccRCC. #kcsm #oncology #GU26
See the whole video here 📷: www.onclive.com/view/dr-chou...
📹 Toni K. Choueiri, MD, of @danafarber.bsky.social discusses prior data that led to the initiation of the LITESPARK-022 trial in ccRCC. #GU26 #oncology
Watch here: www.onclive.com/view/dr-chou...
📊New data suggest PSA response and PSMA-PET tumor volume don’t always align in patients with biochemically recurrent prostate cancer treated with enzalutamide—raising questions about how imaging should guide treatment decisions. #oncology #GU26 #pcsm
Read more here: www.onclive.com/view/psa-res...
Dr. Scott Tyldesley of UBC reports on 15-year ASCENDE-RT data: Brachytherapy boost halves PC-specific mortality (8.6% vs 16.4%, P=.007) but shows no OS benefit.
Read more here: ➡️ https://bit.ly/3OGoIaH
#pcsm #prostatecancer #ASCOGU26 #GU26
Alicia Morgans, MD, MPH, of @danafarber.bsky.social discusses data from a real-world analysis of androgen pathway receptor triplet regimens in mHSPC that were presented during the 2026 Genitourinary Cancers Symposium. #GU26 #prostatecancer #pcsm
Our friends and collaborators at High5Oncology were on the ground in San Francisco
FIND THEM HERE 👉 buff.ly/9peFwD4
Capturing THE KEY discussions from ASCO GU and highlighting the innovations shaping the future of GU oncology and THEIR #GU26 PAGE IS NOW LIVE!!
The IKCC team attended ASCO #GU26 last month in San Francisco to learn about the latest in kidney cancer care and treatment. (1/5)
Check out our latest findings on #Metformin effects on renal function in #mCRPC during #PSMA radiopharmaceutical therapy @ascocancer.bsky.social #GU26
ascopubs.org/doi/abs/10.1...
@ascopost.bsky.social
Our friends and collaborators at High5Oncology were on the ground in San Francisco
FIND THEM HERE 👉 buff.ly/WQZpPkz
Capturing THE KEY discussions from ASCO GU and highlighting the innovations shaping the future of GU oncology and THEIR #GU26 PAGE IS NOW LIVE!!
📹 Watch Matthew D. Galsky, MD, of @mountsinainyc.bsky.social, shed light on the background of the phase 3 KEYNOTE-B15 trial in muscle-invasive bladder cancer. @ascocancer.bsky.social #GU26 #oncology #MIBC
www.onclive.com/view/dr-gals...
The featured video from #GU26 is now available, the Keynote Lecture by Eliezer M. Van Allen, MD, “Reimagining Cancer Research and Care in the Age of Artificial Intelligence.”
Watch: https://bit.ly/47nKDtE
🎙Dr. Monty Pal of @cityofhope.bsky.social and Dr. Andrea Apolo discuss the highlights from #GU26, including key research in bladder, kidney, and prostate cancers, on the latest episode of the #ASCODailyNews Podcast: https://bit.ly/40K3DyK
Our friends and collaborators at High5Oncology were on the ground in San Francisco
FIND THEM HERE 👉 buff.ly/WQZpPkz
Capturing THE KEY discussions from ASCO GU and highlighting the innovations shaping the future of GU oncology and THEIR #GU26 PAGE IS NOW LIVE!!
Read the latest insights from #GU26
From genomic predictors to real‑world combination strategies, experts highlight TP53 status as a potential marker of benefit, broad activity across disease features, and evolving mCRPC approaches
ow.ly/tuHe50Ypb0U
#ASCOGU #ASCOGU2026 #MedEd #MedSky
Our friends from @GuardConsortium 🇪🇸Deliver another Great Informational Capsule, this time direct from #GU26 🇺🇸
We are proud to introduce our Colleague @mjuanfi81 Discussing the Presentation of:
Pathological outcomes and disease-free survival (DFS) in KEYNOTE-905 #BladderCancer
🧬 Experts unpack practice-shaping data in RCC, urothelial, & prostate cancer from the 2026 Genitourinary Cancers Symposium — including updates on LITESPARK-022, KEYNOTE-B15, SunRISE-2 & PEACE-3 📊
#GU26 #oncology #medtwitter #kcsm #pcsm
Check it out 👉 www.onclive.com/view/experts...
Congratulations to Dr. Jamroze on her presentation at ASCO #GU26 in San Francisco last week!
It’s News‑day Tuesday! Does intensifying treatment improve outcomes? At #GU26, Karim Fizazi unpacks first PEACE‑2 results—finding no clinical benefit beyond long‑term ADT + radiotherapy in very high‑risk localized prostate cancer
ow.ly/sQ9G50Yoxrz
The Dennis Deane Arnold Prize,established by a bequest, rewards a USANZ Member who has achieved outstanding laboratory-based research of a urological nature.The inaugural recipient,presented at #USANZ26 was Weranja Ranasinghe, who presented his work at the American Society of Clinical Oncology #GU26
At @ascocancer.bsky.social #GU26, results from @swog.org S1602 ph 3 trial to evaluate BCG strain differences & intradermal BCG priming in high-grade NMIBC:
finds Tokyo BCG is non-inferior to TICE BCG & could mitigate BCG shortage. #BladderCancer
In UroToday at
www.urotoday.com/conference-h...
🧪 Induction #Ipilimumab + #Nivolumab followed by chemoradiotherapy achieved 78% 2-yr bladder-intact event-free survival and strong OS signals in the INDIBLADE trial 👏 📈 @ascocancer.bsky.social #GU26 #oncology Read more➡️ www.onclive.com/view/ipilimu...
What New Research Reveals About Posluma for Detecting Biochemical Recurrence and Bone Metastasis in PCa
www.diagnosticimaging.com/view/new-res...
#radiology #RadRes #GU26 #ProstateCancer
BRCAAway: Abiraterone/olaparib shows survival gain in mCRPC. #GU26 @urologytimes.bsky.social @luriecancer.bsky.social
www.urologytimes.com/view/brcaaway-abirateron...
Now that the ASCO Genitourinary Cancers Symposium 2026 has come to an end, check out our conference coverage all in one convenient location. @ascocancer.bsky.social #GU26 https://bit.ly/400JzIg
Our friends and collaborators at High5Oncology were on the ground in San Francisco
FIND THEM HERE 👉 buff.ly/WQZpPkz
Capturing THE KEY discussions from ASCO GU and highlighting the innovations shaping the future of GU oncology and THEIR #GU26 PAGE IS NOW LIVE!!
Researchers found a 9-month progression-free survival rate with the combination of fruquintinib and serplulimab for treatment-naive advanced non-clear cell renal cell carcinoma (nccRCC). @ascocancer.bsky.social #GU26 #GUCSM https://bit.ly/46APibz
